| Similar Articles |
|---|
 |
The Motley Fool
August 24, 2005
Stephen D. Simpson |
Sweet Air Around ResMed Growing awareness of breathing problems in sleep continues to fuel robust growth at the company. But with a fairly high valuation already in place, these shares aren't a recommended buy.   |
The Motley Fool
January 30, 2006
Stephen D. Simpson |
Respironics in Thin Air Respironics has a great business in the sleep apnea duopoly, but it's still expensive. Investors, take note. |
The Motley Fool
August 9, 2007
Billy Fisher |
ResMed Rests Easy Pillowed by healthy sales, medical-device maker ResMed dreams of future expansion, after reporting a healthy fourth-quarter. |
The Motley Fool
May 5, 2004
Rich Smith |
Has Macrovision No Shame? On Monday after the bell, California-based intellectual property rights defender Macrovision reported yet another fabulous quarter, whether judged by revenues, earnings, or pro forma (Latin for "ad lib") earnings. |
The Motley Fool
August 18, 2005
Stephen D. Simpson |
Kensey Nash Needs to Kick It Up The med-tech company must deliver profit growth if it is to grow or maintain its valuation. |
The Motley Fool
July 28, 2005
Stephen D. Simpson |
Respironics Still Breathes Freely Despite years of solid growth from Respironics, the respiratory market is still underserved and unappreciated. The history of the past few years would suggest you'll get another chance to buy these shares at a somewhat better valuation. |
| Knowledge@Wharton |
Pro Forma Earnings Reports: A Deceptive View of Performance The Securities and Exchange Commission is concerned with a widespread corporate habit -- the growing practice of issuing "pro forma" earnings reports that tend to paint a rosy picture of company results... |
The Motley Fool
November 29, 2005
Rich Smith |
Foolish Forecast: Summing Up Synopsys The software maker expects profits -- pro forma and otherwise. Investors will be faced with a common quandary among companies whose "analysts" insist more on confusing investors than educating them. |
IndustryWeek
February 1, 2002
John S. McClenahen |
Pro Forma's Bottom Line Be careful what you say and how you say it. The Financial Executives International, Morristown, N.J., and the National Investor Relations Institute, Vienna, Va., have come up with guidelines for clear and consistent public statements of corporate earnings. Five key suggestions... |
The Motley Fool
July 21, 2004 |
When "Pro Forma" Is Bad Forma Don't let a company you own fool you with "pro forma" numbers. They're gussied-up numbers that companies would prefer you focus on instead of less attractive numbers that are often more accurate representations of their health or performance. |
The Motley Fool
November 2, 2004
Rich Smith |
Macrovision Takes a Hit Wall Street punishes the digital copy protector for the wrong reasons. |
The Motley Fool
July 26, 2005
Rich Smith |
Sybase's Switcheroo The software maker offers nice earnings and great cash flow, but strange reporting. |
CFO
Edward Teach & Tim Reason |
Lies, Damn Lies, and Pro Forma Pro forma earnings reports may be a cause du jour of reformers, but CFOs aren't about to back down from issuing them... |
The Motley Fool
July 27, 2007
Rich Smith |
Symantec Hits a Flat Note Symantec doesn't provide a complete picture in a quarterly report that shows sales increasing while profits are falling, and a cash flow statement that is suspiciously absent. |
CFO
July 1, 2004
Alix Nyberg |
A Matter of Emphasis Regulation G was supposed to end the abuses of pro forma reporting. Has it succeeded? |
The Motley Fool
October 31, 2005
Stephen D. Simpson |
Integra Needs to Grow From Within Acquired growth is nice, but organic growth is the key to long-term success. Quite frankly, the only way this stock works from a cash flow valuation standpoint is if the company does in fact deliver very good growth over the next 10 years or so. |
The Motley Fool
December 19, 2005
Rich Smith |
Foolish Forecast: Clap for Palm? Palm shows its hand. Depending on a variety of factors, the company expects to report a profits number tomorrow that could range anywhere from $0.38 per diluted share, to $5.20 per share, or from $0.55 up to $0.65. Confusing? You bet. |
The Motley Fool
October 25, 2005
Nathan Parmelee |
Coach's Questionable Call The company's performing very well, so why resort to pro forma reporting? Investors may not want to run out and add Coach to their portfolios just yet. |
The Motley Fool
March 16, 2007
Rich Smith |
Foolish Forecast: Deconstructing Adobe The software company is set to report it fiscal first-quarter 2007 earnings numbers. Investors, here is what you can expect to find. |
The Motley Fool
August 23, 2006
Stephen D. Simpson |
Is Medtronic Sweeping the Deck? Nothing's changing at a deep fundamental level in health care that would impede the growth of this giant med-tech corporation. However, investors need to proceed with caution. |
The Motley Fool
January 7, 2004
Rex Moore |
Constellation Brands Shines On The pieces are falling in place for the world's largest wine producer. |
The Motley Fool
August 6, 2004
Rich Smith |
Reed Elsevier's Fine Print European publisher illustrates how pro forma accounting knows no borders. |
The Motley Fool
June 15, 2007
Rich Smith |
Foolish Forecast: Resuming Progress? After posting back-to-back earnings misses, Progress Software pulled out of its slump last quarter and beat the estimators. Will it begin a new streak, and start off next week with a bang, when it reports second-quarter 2007 earnings? |
The Motley Fool
May 14, 2007
Rich Smith |
WebSideStory Opens New Chapter While Wall Street went ga-ga over the newly re-named marketing data analyzer's first-quarter pro forma profits, investors should be aware that from a free cash flow perspective, things don't read as nicely. |
American Family Physician
October 1, 2005 |
Sleep Apnea A patient hand-out on the disorder and how to treat it. |
The Motley Fool
January 24, 2011
Selena Maranjian |
Make Money in Medical Devices the Easy Way Get instant exposure to diversification and possible profits. |
The Motley Fool
May 9, 2007
Billy Fisher |
A Growing Bandwagon at VIASYS The medical device maker has been expanding globally. Investors, take note. |
American Family Physician
March 1, 2004 |
Sleep Apnea in Children Snoring happens during sleep when the throat muscles relax and the airway narrows. When the throat muscles relax, the nose is blocked. Snoring is common in children and may be a cause for concern. |
The Motley Fool
May 22, 2006
Rich Smith |
Foolish Forecast: Phillips-Van Heusen Analysts have high hopes for this clothier as it prepares to report its first-quarter 2006 earnings. Here's a quick rundown of what Wall Street expects, what the company's already done, and what you might want to look for in Tuesday's report. |
The Motley Fool
January 24, 2006
Rich Smith |
Foolish Forecast: Simply CNS Analysts believe that CNS will grow at an annualized rate of 18% in the long term. That's tremendous, but perhaps not enough to justify its P/E ratio of 21, or its price-to-free cash flow ratio of 21. |
InternetNews
April 21, 2004
Susan Kuchinskas |
eBay Nation Powers its Q1 Financials If the online marketplace were a country, it would be the world's eleventh most populous nation, behind Japan and ahead of Mexico. |
The Motley Fool
August 22, 2006
Rich Smith |
Foolish Forecast: Will Credence Clear Water? Can semiconductor-tester Credence Systems keep up its recent profitable trend, and make it three in a row for positive (pro forma only) earnings when it reports its fiscal third-quarter 2006 numbers on Thursday? Investors, take note. |
